However, AML and MDS patients with TP53 mutations show a better response to DAC than those with wild-type (WT) TP53, a typical tumor suppressor gene, making it difficult to explain the therapeutic effect of HMAs in terms of tumor suppressor gene activation15. This evidence concerns the gene TP53 and acute myeloid leukemia.